CO5070688A1 - Procedimiento para la cristalizacion de un derivado tetrahidropiridina, a las nuevas formas cristalinas asi obtenidas y a las composiciones farmaceuticas que contienen - Google Patents

Procedimiento para la cristalizacion de un derivado tetrahidropiridina, a las nuevas formas cristalinas asi obtenidas y a las composiciones farmaceuticas que contienen

Info

Publication number
CO5070688A1
CO5070688A1 CO97074792A CO97074792A CO5070688A1 CO 5070688 A1 CO5070688 A1 CO 5070688A1 CO 97074792 A CO97074792 A CO 97074792A CO 97074792 A CO97074792 A CO 97074792A CO 5070688 A1 CO5070688 A1 CO 5070688A1
Authority
CO
Colombia
Prior art keywords
crystallization
procedure
tetrahydropiridine
derivative
pharmaceutical compositions
Prior art date
Application number
CO97074792A
Other languages
English (en)
Spanish (es)
Inventor
Antoine Caron
Bruno Franc
Monnier Olivier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of CO5070688A1 publication Critical patent/CO5070688A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO97074792A 1996-12-23 1997-12-23 Procedimiento para la cristalizacion de un derivado tetrahidropiridina, a las nuevas formas cristalinas asi obtenidas y a las composiciones farmaceuticas que contienen CO5070688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (1)

Publication Number Publication Date
CO5070688A1 true CO5070688A1 (es) 2001-08-28

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97074792A CO5070688A1 (es) 1996-12-23 1997-12-23 Procedimiento para la cristalizacion de un derivado tetrahidropiridina, a las nuevas formas cristalinas asi obtenidas y a las composiciones farmaceuticas que contienen

Country Status (38)

Country Link
EP (1) EP0950050B1 (enExample)
JP (2) JP4499188B2 (enExample)
KR (1) KR100586670B1 (enExample)
CN (1) CN1129580C (enExample)
AR (1) AR009672A1 (enExample)
AT (1) ATE307802T1 (enExample)
AU (1) AU736697B2 (enExample)
BR (1) BR9714081A (enExample)
CA (1) CA2275596C (enExample)
CO (1) CO5070688A1 (enExample)
CZ (1) CZ296689B6 (enExample)
DE (1) DE69734460T2 (enExample)
DK (1) DK0950050T3 (enExample)
DZ (1) DZ2383A1 (enExample)
EE (1) EE04188B1 (enExample)
EG (1) EG21567A (enExample)
ES (1) ES2251038T3 (enExample)
FR (1) FR2757543B1 (enExample)
HR (1) HRP970699B1 (enExample)
HU (1) HU227425B1 (enExample)
IL (1) IL129938A (enExample)
IN (1) IN186976B (enExample)
IS (1) IS2357B (enExample)
MY (1) MY118015A (enExample)
NO (1) NO312364B1 (enExample)
NZ (1) NZ336130A (enExample)
PL (1) PL190494B1 (enExample)
RS (1) RS49882B (enExample)
RU (1) RU2192416C2 (enExample)
SA (1) SA98180971B1 (enExample)
SI (1) SI0950050T1 (enExample)
SK (1) SK285088B6 (enExample)
TR (1) TR199901363T2 (enExample)
TW (1) TW518322B (enExample)
UA (1) UA60324C2 (enExample)
UY (1) UY24825A1 (enExample)
WO (1) WO1998028271A1 (enExample)
ZA (1) ZA9711576B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
JP5504334B2 (ja) 2010-03-12 2014-05-28 株式会社日本触媒 吸水性樹脂の製造方法
EP2643294B1 (en) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited An improved rilpivirine process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
SK82899A3 (en) 1999-12-10
RS49882B (sr) 2008-08-07
UA60324C2 (uk) 2003-10-15
FR2757543A1 (fr) 1998-06-26
KR100586670B1 (ko) 2006-06-07
WO1998028271A1 (fr) 1998-07-02
EE04188B1 (et) 2003-12-15
FR2757543B1 (fr) 1999-04-02
UY24825A1 (es) 1998-04-21
ES2251038T3 (es) 2006-04-16
TR199901363T2 (xx) 1999-08-23
EE9900264A (et) 2000-02-15
SK285088B6 (sk) 2006-06-01
JP2009197022A (ja) 2009-09-03
NO993076D0 (no) 1999-06-22
MY118015A (en) 2004-08-30
IL129938A (en) 2004-06-20
TW518322B (en) 2003-01-21
JP2001507012A (ja) 2001-05-29
HU227425B1 (en) 2011-05-30
JP4499188B2 (ja) 2010-07-07
AR009672A1 (es) 2000-04-26
ATE307802T1 (de) 2005-11-15
SI0950050T1 (sl) 2006-04-30
IL129938A0 (en) 2000-02-29
NO312364B1 (no) 2002-04-29
CA2275596A1 (en) 1998-07-02
YU28999A (sh) 2003-01-31
CN1129580C (zh) 2003-12-03
IS5076A (is) 1999-06-10
IS2357B (is) 2008-04-15
CA2275596C (en) 2005-10-11
NO993076L (no) 1999-06-22
NZ336130A (en) 2001-01-26
AU736697B2 (en) 2001-08-02
SA98180971B1 (ar) 2006-09-13
KR20000069504A (ko) 2000-11-25
HRP970699A2 (en) 1998-10-31
DZ2383A1 (fr) 2002-12-28
EP0950050B1 (fr) 2005-10-26
PL190494B1 (pl) 2005-12-30
HUP0001387A2 (hu) 2000-09-28
DE69734460T2 (de) 2006-07-06
HK1024002A1 (en) 2000-09-29
BR9714081A (pt) 2000-05-09
ZA9711576B (en) 1998-06-25
DE69734460D1 (de) 2005-12-01
CZ296689B6 (cs) 2006-05-17
EP0950050A1 (fr) 1999-10-20
EG21567A (en) 2001-12-31
DK0950050T3 (da) 2006-01-23
HUP0001387A3 (en) 2002-03-28
CN1241180A (zh) 2000-01-12
PL334256A1 (en) 2000-02-14
AU5668498A (en) 1998-07-17
CZ229299A3 (cs) 1999-09-15
IN186976B (enExample) 2001-12-22
HRP970699B1 (en) 2007-03-31
RU2192416C2 (ru) 2002-11-10

Similar Documents

Publication Publication Date Title
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
AR032626A1 (es) Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
CO5070574A1 (es) Derivado del acido fenoxiacetico y composicion farmaceutica que lo contiene
CA2333938A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
AP2001002299A0 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
AP2002002531A0 (en) 4-Carboboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inihibitor.
AR045793A1 (es) Compuestos derivados de 3-heterociclil-indol
UY27700A1 (es) Compuestos oxo - azabiclícos.
BR0315840A (pt) Fosfolipìdeos de anel substituìdo anti-protozoários
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR032622A1 (es) Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos
AR046768A1 (es) Derivados de piridin-tetrazol, metodos de obtencion y composiciones farmaceuticas
AR042343A1 (es) Derivados de pirazina que presentan efecto inhibidor selectivo sobre gsk3, proceso de preparacion y formulaciones farmaceuticas que los contienen
AR035730A1 (es) Derivados de 2-arilamino-2,3-dihidrotiazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento
UY24825A1 (es) "procedimiento para la cristalizacion de un derivado de la tetrahidropiridina"
AR019953A1 (es) Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizado
Wallis et al. Molecular Rearrangements Involving Optically Active Radicals. III. The Lossen Rearrangement of Optically Active Hydroxamic Acids
DE3787844D1 (de) Thioester und dessen Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen.
ATE127465T1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
ATE294155T1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten